CBDX: AI 评分 44/100 — AI 分析 (4月 2026)

Curative Biosciences, Inc. is a healthcare company focused on developing and commercializing therapeutics using hemp-derived Cannabidiol. The company aims to manufacture and market natural health products within the medical cannabis industry.

Key Facts: AI Score: 44/100 Sector: Healthcare

公司概况

概要：

Curative Biosciences, Inc. is a specialty drug manufacturer focusing on hemp-derived Cannabidiol (CBD) therapeutics and natural health products. Operating in the evolving medical cannabis industry, the company aims to capitalize on the growing market for CBD-based treatments, though it faces competition and regulatory hurdles common to the sector.

CBDX是做什么的？

Curative Biosciences, Inc., formerly known as Amaize Beverage Corporation, was founded in 2009 and rebranded in August 2017 to focus on the burgeoning medical cannabis industry. Headquartered in Miami, Florida, the company is dedicated to the development and commercialization of therapeutics derived from hemp-based Cannabidiol (CBD). Curative Biosciences intends to manufacture and market natural health products, positioning itself to serve a growing market segment seeking alternative and natural remedies. The company's strategy involves leveraging the therapeutic potential of CBD to create products that address various health and wellness needs. As a player in the specialty and generic drug manufacturing sector, Curative Biosciences navigates a complex regulatory landscape and competes with other companies exploring cannabinoid-based treatments. The company's success depends on its ability to innovate, secure regulatory approvals, and effectively market its products to consumers and healthcare professionals.

CBDX的投资论点是什么？

Curative Biosciences, Inc. presents a speculative investment opportunity within the high-growth, yet volatile, medical cannabis industry. The company's focus on hemp-derived Cannabidiol (CBD) therapeutics aligns with increasing consumer interest in natural health products. However, the company's current financials, including a negative P/E ratio of -0.03 and a market cap of $0.00B, indicate significant risk. Growth catalysts include potential regulatory changes favoring CBD products and successful development and commercialization of novel therapeutics. The company's high beta of 64.72 suggests extreme volatility relative to the market, making it suitable only for investors with a high-risk tolerance.

CBDX在哪个行业运营？

Curative Biosciences operates within the Drug Manufacturers - Specialty & Generic industry, which is experiencing growth due to increasing demand for specialized and affordable medications. The medical cannabis sector, in particular, is expanding rapidly as regulations surrounding cannabis and CBD products evolve. Companies like Curative Biosciences are positioning themselves to capitalize on this trend, but they face competition from established pharmaceutical companies and other emerging players. The industry is also subject to regulatory uncertainty and evolving consumer preferences, requiring companies to be agile and innovative.

Drug Manufacturers - Specialty & Generic

Healthcare

CBDX有哪些增长机遇？

Expansion into New Therapeutic Areas: Curative Biosciences can explore developing CBD-based therapeutics for specific medical conditions such as anxiety, pain management, and sleep disorders. The market for these treatments is substantial, with the global pain management market projected to reach $83 billion by 2027. Success in clinical trials and regulatory approvals would be critical for capturing market share. Timeline: 2-5 years for product development and regulatory approval.
Strategic Partnerships: Collaborating with established pharmaceutical companies or healthcare providers could provide Curative Biosciences with access to resources, expertise, and distribution channels. Joint ventures or licensing agreements could accelerate product development and market penetration. This strategy can reduce the financial burden and time-to-market for new products. Timeline: 1-3 years for establishing partnerships and launching collaborative projects.
Geographic Expansion: Curative Biosciences can expand its market reach by targeting new geographic regions where CBD products are legal and in demand. Entering international markets, particularly in Europe and Asia, could significantly increase revenue streams. Adapting products and marketing strategies to local regulations and consumer preferences will be crucial for success. Timeline: 2-4 years for market entry and establishing distribution networks.
Development of Novel Delivery Systems: Innovating in the delivery of CBD therapeutics, such as through transdermal patches, inhalers, or sublingual formulations, could enhance product efficacy and patient compliance. These novel delivery systems can offer advantages over traditional oral formulations, such as improved bioavailability and faster onset of action. Timeline: 3-5 years for research, development, and regulatory approval.
Focus on Research and Development: Investing in rigorous scientific research to validate the therapeutic benefits of CBD and develop proprietary formulations can create a competitive advantage for Curative Biosciences. Conducting clinical trials and publishing research findings can enhance the credibility of its products and attract partnerships with healthcare professionals. Timeline: Ongoing, with continuous investment in research and development.

Curative Biosciences operates in the high-growth medical cannabis industry, focusing on hemp-derived Cannabidiol (CBD) therapeutics.
The company intends to manufacture and market natural health products, targeting consumers seeking alternative remedies.
Curative Biosciences has a negative P/E ratio of -0.03, indicating it is not currently profitable.
The company's market capitalization is $0.00B, reflecting its early stage and associated risks.
Curative Biosciences exhibits a high beta of 64.72, suggesting significant volatility compared to the overall market.

CBDX提供哪些产品和服务？

Develop therapeutics using hemp-derived Cannabidiol (CBD).
Focus on the medical cannabis industry.
Manufacture and market natural health products.
Research and develop innovative CBD formulations.
Target specific medical conditions with CBD-based treatments.
Navigate the regulatory landscape for cannabis products.
Seek strategic partnerships to expand market reach.

CBDX如何赚钱？

Develop and commercialize CBD-based therapeutics.
Manufacture and sell natural health products.
Generate revenue through product sales and licensing agreements.
Invest in research and development to create proprietary formulations.

Consumers seeking natural health products.
Patients seeking alternative treatments for medical conditions.
Healthcare professionals interested in CBD-based therapies.
Retailers and distributors of health and wellness products.

Proprietary CBD formulations.
Strategic partnerships with healthcare providers.
Early mover advantage in emerging markets.
Strong brand reputation for quality and efficacy.

什么因素可能推动CBDX股价上涨？

Upcoming: Potential regulatory changes favoring CBD products.
Upcoming: Successful development and commercialization of novel therapeutics.
Upcoming: Strategic partnerships with established pharmaceutical companies.
Ongoing: Increasing consumer interest in natural health products.
Ongoing: Expansion into new geographic markets.

CBDX的主要风险是什么？

Potential: Changing regulatory landscape for cannabis products.
Potential: Increased competition from larger companies.
Potential: Negative public perception of cannabis products.
Ongoing: Limited financial resources.
Ongoing: Dependence on regulatory approvals.

CBDX的核心优势是什么？

Focus on high-growth medical cannabis industry.
Potential for proprietary CBD formulations.
Early mover advantage in emerging markets.
Experienced management team.

CBDX的劣势是什么？

Limited financial resources.
Dependence on regulatory approvals.
Intense competition from established players.
Lack of clinical trial data to support product claims.

CBDX有哪些机遇？

Expansion into new therapeutic areas.
Strategic partnerships with healthcare providers.
Geographic expansion into international markets.
Development of novel delivery systems.

CBDX面临哪些威胁？

Changing regulatory landscape.
Increased competition from larger companies.
Negative public perception of cannabis products.
Potential for adverse side effects from CBD treatments.

CBDX的竞争对手是谁？

AcuraStem, Inc. — Focuses on neurodegenerative diseases. — (ACUR)
Azafran Group, Inc. — Offers diverse hemp and CBD products. — (AZFL)
Cannabis Consortium Inc — Operates in the cannabis cultivation and distribution. — (CNNC)
Flora Growth Corp. — Focuses on cannabis cultivation and distribution. — (FLHLF)
Green Medicine Ventures Inc — Develops cannabis-based pharmaceutical products. — (GMVDF)

Key Metrics

MoonshotScore: 44/100

Company Profile

CEO: Katherine T. Alverson West
Headquarters: Miami, US
Founded: 2004

AI Insight

AI analysis pending for CBDX

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Curative Biosciences, Inc. do?

Curative Biosciences, Inc. is a healthcare company focused on developing and commercializing therapeutics using hemp-derived Cannabidiol (CBD). The company intends to manufacture and market natural health products, positioning itself within the medical cannabis industry. By leveraging the therapeutic potential of CBD, Curative Biosciences aims to address various health and wellness needs, targeting consumers seeking alternative and natural remedies. The company navigates a complex regulatory landscape and competes with other companies exploring cannabinoid-based treatments.

What do analysts say about CBDX stock?

As of March 18, 2026, there is no readily available analyst coverage for Curative Biosciences, Inc. (CBDX). Given its OTC Other tier listing and limited market capitalization, the company may not be actively tracked by major brokerage firms. Investors should conduct their own due diligence and consider the company's financial condition, growth prospects, and the risks associated with investing in OTC stocks before making any investment decisions. The absence of analyst ratings should be viewed as a lack of consensus, not necessarily a negative indicator.

What are the main risks for CBDX?

Investing in Curative Biosciences, Inc. carries significant risks, typical of companies in the OTC market and the evolving cannabis industry. These include regulatory uncertainty surrounding CBD products, intense competition from established pharmaceutical companies and other emerging players, and the potential for negative public perception of cannabis-related products. The company's limited financial resources and dependence on regulatory approvals also pose substantial risks. Additionally, the OTC Other tier listing indicates a lack of transparency and regulatory oversight, increasing the risk of fraud or manipulation.